Romosozumab is a humanized monoclonal antibody indicated for the treatment of osteoperosis in postmenopausal women at high risk of fracture and patients who have failed in other treatments or are intolerant to other osteoperosis therapies 9.
Romosozumab prevents bone resorption and induces the formation of bone though it is associated with an increased risk of cardiac death, heart attack and stroke in one study 7, 8.
In a comparison study of post menopausal women with osteoporosis and a past fracture, romosozumab for 12 months followed by alendronic acid for 12 months was superior to alendronic acid alone for 24 months 3.
Romosozumab also demonstrates a faster and larger increase in bone density than teriparatide 4.
Romosozumab is marketed in the United States by Amgen under the brand name Evinity7.
Romosozumab was granted FDA approval on April 9,2019.
Applications:Suitable for use in ELISA and SDS-PAGE.
Other applications not*+- tested.
Recommended Dilution:Optimal dilutions to be determined by the researcher.
Storage and Stability:May be stored at 4℃ for short-term only.
Aliquot to avoid repeated freezing and thawing.
Store at -20℃.
Aliquots are stable for 12 months after receipt.
For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
仕様
Size：100ug
抗体種類：Mab
宿主：human
Grade：Highly Purified
Purity：≥95%
Form：Supplied as a liquid in PBS, pH 7.5.
Specificity：Recognizes Romosozumab (SOST).
Isotype：IgG2,k
Calc Applications Abbrev：E
Immunogen：Recombinant protein corresponding to humanized SOST [Homo sapiens], expressed in CHO cells.
